Clinical Trials Browser

Unknown × INDUSTRY × Pemetrexed × Clear all

NCT06116240 2023-11-03

A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

Phase 1 Unknown

Other solid neoplasm

Solid Tumor

NCT06110663 2023-11-01

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03952403 2023-08-08

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

Carcinoma

NCT05794477 2023-06-02

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT05741021 2023-02-24

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05346952 2022-04-26

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Phase 3 Unknown

Advanced Non-squamous Non-small Cell Lung Cancer

NCT02448797 2021-07-20

EVIDENCE

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

NCT03912389 2020-09-17

DOMAJOR

Phase 3 Unknown

Non-Squamous Non-Small Cell Neoplasm of Lung

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

PD-L1 Positive Non-small Cell Lung Cancer

NCT04054531 2019-09-10

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Phase 4 Unknown

Adenocarcinoma

NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01707329 2015-09-09

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Phase 4 Unknown

Adenocarcinoma